ABBV - AbbVie Stock Price, News & Analysis

$94.72 0.25 (0.26 %)
(As of 11/24/2017 04:00 PM ET)
Previous Close$94.47
Today's Range$94.97 - $93.55
52-Week Range$58.60 - $98.26
Volume1.93 million shs
Average Volume6.18 million shs
Market Capitalization$150.81 billion
P/E Ratio17.79
Dividend Yield2.70%
Beta1.51

About AbbVie (NYSE:ABBV)

AbbVie logoAbbVie Inc. (AbbVie) is a research-based biopharmaceutical company. The Company is engaged in the discovery, development, manufacture and sale of a range of pharmaceutical products. Its products are focused on treating conditions, such as chronic autoimmune diseases in rheumatology, gastroenterology and dermatology; oncology, including blood cancers; virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV); neurological disorders, such as Parkinson's disease and multiple sclerosis; metabolic diseases, including thyroid disease and complications associated with cystic fibrosis, and other serious health conditions. It offers products in various categories, including HUMIRA (adalimumab), Oncology products, Virology Products, Additional Virology products, Metabolics/Hormones products, Endocrinology products and other products, which include Duopa and Duodopa (carbidopa and levodopa), Anesthesia products and ZINBRYTA (daclizumab).


Industry, Sector and Symbol

Industry Specialty & Advanced Pharmaceuticals
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNYSE:ABBV
CUSIP00287Y10

Debt

Debt-to-Equity Ratio5.08%
Current Ratio1.45%
Quick Ratio1.32%

Price-To-Earnings

Trailing P/E Ratio17.79
Forward P/E Ratio17.07
P/E Growth1.31

Sales & Book Value

Annual Sales$25.64 billion
Price / Sales5.90
Cash Flow$5.61 per share
Price / Cash16.88
Book Value$4.19 per share
Price / Book22.61

Dividend

Annual Dividend$2.56
Dividend Yield2.7%

Profitability

Trailing EPS$4.11
Net Income$5.95 billion
Net Margins24.38%
Return on Equity153.80%
Return on Assets12.83%

Miscellaneous

Employees30,000
Outstanding Shares1,596,430,000

Frequently Asked Questions for AbbVie (NYSE:ABBV)

What is AbbVie's stock symbol?

AbbVie trades on the New York Stock Exchange (NYSE) under the ticker symbol "ABBV."

How often does AbbVie pay dividends? What is the dividend yield for AbbVie?

AbbVie declared a quarterly dividend on Friday, October 27th. Investors of record on Friday, January 12th will be given a dividend of $0.71 per share on Thursday, February 15th. This represents a $2.84 dividend on an annualized basis and a yield of 3.00%. The ex-dividend date of this dividend is Thursday, January 11th. This is a positive change from AbbVie's previous quarterly dividend of $0.64. View AbbVie's Dividend History.

How will AbbVie's stock buyback program work?

AbbVie declared that its Board of Directors has authorized a share buyback program on Sunday, April 9th 2017, which permits the company to repurchase $5,000,000,000.00 in outstanding shares, according to EventVestor. This repurchase authorization permits the company to purchase up to 5% of its stock through open market purchases. Stock repurchase programs are usually a sign that the company's leadership believes its shares are undervalued.

How were AbbVie's earnings last quarter?

AbbVie Inc. (NYSE:ABBV) released its quarterly earnings data on Friday, October, 27th. The company reported $1.41 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $1.39 by $0.02. The company earned $7 billion during the quarter, compared to analysts' expectations of $7 billion. AbbVie had a return on equity of 153.80% and a net margin of 24.38%. The company's quarterly revenue was up 8.8% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.21 EPS. View AbbVie's Earnings History.

When will AbbVie make its next earnings announcement?

AbbVie is scheduled to release their next quarterly earnings announcement on Friday, January, 26th 2018. View Earnings Estimates for AbbVie.

What guidance has AbbVie issued on next quarter's earnings?

AbbVie issued an update on its FY18 earnings guidance on Friday, October, 27th. The company provided EPS guidance of $6.37-6.57 for the period, compared to the Thomson Reuters consensus EPS estimate of $6.59. AbbVie also updated its FY17 guidance to $5.53-5.55 EPS.

Where is AbbVie's stock going? Where will AbbVie's stock price be in 2017?

16 equities research analysts have issued twelve-month price targets for AbbVie's stock. Their predictions range from $60.00 to $115.00. On average, they anticipate AbbVie's stock price to reach $95.60 in the next year. View Analyst Ratings for AbbVie.

What are Wall Street analysts saying about AbbVie stock?

Here are some recent quotes from research analysts about AbbVie stock:

  • 1. According to Zacks Investment Research, "AbbVie reported mixed Q3 results.  While earnings beat estimates, revenues came in line. Humira and Imbruvica kept up the strong performance. Meanwhile, AbbVie raised its earnings outlook for the year backed by a strong year-to-date performance.  Despite new competition, it raised its long-term target for Humira sales based on strong demand trends for the drug. Meanwhile, the past 2-3 months have been strong for the company as it presented promising data from several pivotal studies, gained regulatory approvals in the U.S., Europe, and Japan for its competitive HCV medicine Mavyret and FDA approval for the sixth indication for Imbrivica and settled its Humira patent disputes with Amgen. Also, several pivotal data readouts and regulatory milestones are expected in 2018. AbbVie’s shares have outperformed the industry this year so far. However, HCV sales continue to be hurt by intensifying competition." (11/1/2017)
  • 2. UBS AG analysts commented, "For other pipeline products, we already included appropriate risk-adj estimates and in some cases significant risk adj sales (Rova-T)," (9/25/2017)
  • 3. Jefferies Group LLC analysts commented, "ABBV's IPR with CHRS will be heard this week, which looks challenging in light of the prior institution decision. However, the market already expects ABBV to lose and we do not see the '135 patent alone as critical to delaying biosimilars, indicating positive asymmetry in our view. We look at the key IPR arguments as well as the risk/ reward around the decision expected in May as we prepare to attend the hearing." (2/14/2017)

Are investors shorting AbbVie?

AbbVie saw a decline in short interest during the month of October. As of October 13th, there was short interest totalling 14,213,032 shares, a decline of 21.2% from the September 29th total of 18,045,411 shares. Based on an average trading volume of 4,423,568 shares, the short-interest ratio is presently 3.2 days. Approximately 0.9% of the company's shares are sold short.

Who are some of AbbVie's key competitors?

Who are AbbVie's key executives?

AbbVie's management team includes the folowing people:

  • Richard A. Gonzalez, Chairman of the Board, Chief Executive Officer (Age 63)
  • William J. Chase, Executive Vice President, Chief Financial Officer (Age 49)
  • Michael Severino M.D., Executive Vice President - Research & Development, Chief Scientific Officer (Age 51)
  • Laura J. Schumacher, Executive Vice President, External Affairs, General Counsel and Corporate Secretary (Age 53)
  • Carlos Alban, Executive Vice President - Commercial Operations (Age 54)
  • Henry O. Gosebruch, Executive Vice President, Chief Strategy Officer (Age 44)
  • Timothy J. Richmond, Senior Vice President - Human Resources (Age 50)
  • Azita Saleki-Gerhardt Ph.D., Senior Vice President - Operations (Age 53)
  • Robert A. Michael, Vice President, Controller (Age 46)
  • Robert J. Alpern M.D., Independent Director (Age 66)

Who owns AbbVie stock?

AbbVie's stock is owned by a variety of of retail and institutional investors. Top institutional shareholders include Bank of New York Mellon Corp (1.05%), Legal & General Group Plc (0.51%), Epoch Investment Partners Inc. (0.49%), Capital International Investors (0.49%), American International Group Inc. (0.48%) and Ameriprise Financial Inc. (0.45%). Company insiders that own AbbVie stock include Azita Saleki-Gerhardt, Carlos Alban, Edward J Rapp, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Thomas A Hurwich, Timothy J Richmond and William J Chase. View Institutional Ownership Trends for AbbVie.

Who sold AbbVie stock? Who is selling AbbVie stock?

AbbVie's stock was sold by a variety of institutional investors in the last quarter, including Woodford Investment Management Ltd, Ameriprise Financial Inc., Janus Henderson Group PLC, Alyeska Investment Group L.P., Schroder Investment Management Group, Nordea Investment Management AB, Santa Barbara Asset Management LLC and Comerica Bank. Company insiders that have sold AbbVie company stock in the last year include Azita Saleki-Gerhardt, Carlos Alban, Henry O Gosebruch, Laura J Schumacher, Michael Severino, Richard A Gonzalez, Robert A Michael, Timothy J Richmond and William J Chase. View Insider Buying and Selling for AbbVie.

Who bought AbbVie stock? Who is buying AbbVie stock?

AbbVie's stock was acquired by a variety of institutional investors in the last quarter, including Jennison Associates LLC, Capital International Investors, KBC Group NV, Assenagon Asset Management S.A., Canada Pension Plan Investment Board, APG Asset Management N.V., PGGM Investments and Artemis Investment Management LLP. View Insider Buying and Selling for AbbVie.

How do I buy AbbVie stock?

Shares of AbbVie can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is AbbVie's stock price today?

One share of AbbVie stock can currently be purchased for approximately $94.72.

How big of a company is AbbVie?

AbbVie has a market capitalization of $150.81 billion and generates $25.64 billion in revenue each year. The company earns $5.95 billion in net income (profit) each year or $4.11 on an earnings per share basis. AbbVie employs 30,000 workers across the globe.

How can I contact AbbVie?

AbbVie's mailing address is 1 NORTH WAUKEGAN ROAD, NORTH CHICAGO IL, 60064. The company can be reached via phone at 847-932-7900.


MarketBeat Community Rating for AbbVie (ABBV)

Community Ranking:  3.2 out of 5 (star star star)
Outperform Votes:  631 (Vote Outperform)
Underperform Votes:  368 (Vote Underperform)
Total Votes:  999
MarketBeat's community ratings are surveys of what our community members think about AbbVie and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for AbbVie (NYSE:ABBV)

  (How are Consensus Ratings Calculated?)
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: BuyBuyBuyHold
Consensus Rating Score: 2.642.592.522.44
Ratings Breakdown: 0 Sell Ratings
9 Hold Ratings
12 Buy Ratings
1 Strong Buy Ratings
0 Sell Ratings
9 Hold Ratings
13 Buy Ratings
0 Strong Buy Ratings
0 Sell Ratings
11 Hold Ratings
9 Buy Ratings
1 Strong Buy Ratings
0 Sell Ratings
11 Hold Ratings
6 Buy Ratings
1 Strong Buy Ratings
Consensus Price Target: $92.96$91.26$74.01$70.10
Price Target Upside: 1.68% downside0.46% downside5.10% upside6.12% upside

Consensus Price Target History for AbbVie (NYSE:ABBV)

Price Target History for AbbVie (NYSE:ABBV)

Analysts' Ratings History for AbbVie (NYSE:ABBV)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/21/2017BMO Capital MarketsReiterated RatingHold$84.00N/AView Rating Details
11/21/2017Societe GeneraleBoost Price TargetN/AView Rating Details
10/30/2017SunTrust Banks, Inc.Reiterated RatingBuyN/AView Rating Details
10/30/2017Leerink SwannLower Price TargetOutperform$108.00 -> $107.00N/AView Rating Details
10/27/2017Piper Jaffray CompaniesBoost Price TargetOverweight$115.00N/AView Rating Details
10/16/2017Jefferies Group LLCBoost Price TargetBuy$107.00 -> $115.00N/AView Rating Details
10/13/2017Barclays PLCBoost Price TargetEqual Weight$90.00N/AView Rating Details
10/11/2017Cowen IncUpgradeMarket Perform -> Outperform$91.17 -> $105.00N/AView Rating Details
10/1/2017Credit Suisse GroupReiterated RatingNeutral$74.00 -> $94.00MediumView Rating Details
9/30/2017Evercore ISIReiterated RatingOutperform$95.00 -> $100.00MediumView Rating Details
9/29/2017ArgusBoost Price TargetBuy$90.00 -> $110.00LowView Rating Details
9/29/2017Morgan StanleyBoost Price TargetEqual Weight$70.00 -> $95.00LowView Rating Details
9/28/2017Deutsche Bank AGBoost Price TargetHold$88.00LowView Rating Details
9/8/2017Goldman Sachs Group, Inc. (The)Reiterated RatingBuy$85.00 -> $100.00LowView Rating Details
12/8/2016William BlairReiterated RatingOutperform$76.00N/AView Rating Details
11/28/2016Citigroup Inc.DowngradeBuy -> Neutral$60.00N/AView Rating Details
9/8/2016J P Morgan Chase & CoDowngradeOverweight -> Neutral$75.00 -> $73.00N/AView Rating Details
9/1/2016Raymond James Financial, Inc.Initiated CoverageOutperform$82.00N/AView Rating Details
12/18/2015Atlantic SecuritiesInitiated CoverageNeutral$59.00N/AView Rating Details
(Data available from 11/24/2015 forward)

Earnings

Earnings History and Estimates Chart for AbbVie (NYSE:ABBV)

Earnings by Quarter for AbbVie (NYSE:ABBV)

Earnings History by Quarter for AbbVie (NYSE ABBV)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
1/25/2018N/AView Earnings Details
10/27/2017Q3 2017$1.39$1.41$7.00 billion$7.00 billionViewN/AView Earnings Details
7/28/2017Q2 2017$1.40$1.42$6.93 billion$6.94 billionViewN/AView Earnings Details
4/27/2017Q1 2017$1.26$1.28$6.49 billion$6.54 billionViewN/AView Earnings Details
1/27/2017Q416$1.20$1.20$6.92 billion$6.78 billionViewListenView Earnings Details
10/28/2016Q316$1.21$1.21$6.55 billion$6.43 billionViewListenView Earnings Details
7/29/2016Q216$1.20$1.26$6.20 billion$6.43 billionViewListenView Earnings Details
4/28/2016Q116$1.14$1.15$6.03 billion$5.96 billionViewListenView Earnings Details
1/29/2016Q415$1.12$1.13$6.41 billion$6.36 billionViewListenView Earnings Details
10/30/2015Q315$1.08$1.13$5.90 billion$4.94 billionViewListenView Earnings Details
7/24/2015Q215$1.06$1.08$5.60 billion$5.48 billionViewListenView Earnings Details
4/23/2015Q115$0.85$0.94$718.50 million$5.04 billionViewListenView Earnings Details
1/30/2015Q414$0.86$0.89$5.34 billion$5.45 billionViewListenView Earnings Details
10/31/2014Q3$0.77$0.89$4.82 million$5.02 millionViewListenView Earnings Details
7/25/2014Q214$0.76$0.82$4.70 billion$4.93 billionViewListenView Earnings Details
4/25/2014Q114$0.68$0.71$4.33 billion$4.56 billionViewListenView Earnings Details
1/31/2014Q413$0.82$0.82$5.10 billion$5.11 billionViewListenView Earnings Details
10/25/2013Q313$0.78$0.82$4.52 billion$4.66 billionViewListenView Earnings Details
7/26/2013Q2 2013$0.79$0.92$4.54 billion$4.69 billionViewListenView Earnings Details
4/26/2013Q1 2013$0.67$0.68$4.17 billion$4.33 billionViewListenView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for AbbVie (NYSE:ABBV)
Current Year EPS Consensus Estimate: $5.55 EPS
Next Year EPS Consensus Estimate: $6.53 EPS

Dividends

Current Dividend Information for AbbVie (NYSE:ABBV)

Next Dividend:2/15/2018
Annual Dividend:$2.56
Dividend Yield:2.70%
Dividend Growth:12.50% (3 Year Average)
Payout Ratio:62.29% (Trailing 12 Months of Earnings)
46.13% (Based on This Year's Estimates)
39.20% (Based on Next Year's Estimates)
Track Record:44 Years of Consecutive Dividend Growth
Frequency:Quarterly Dividend
Dividend Payments by Quarter for AbbVie (NYSE:ABBV)

Dividend History by Quarter for AbbVie (NYSE ABBV)

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
10/27/2017Quarterly$0.713.12%1/11/20181/12/20182/15/2018
9/8/2017Quarterly$0.642.94%10/12/201710/13/201711/15/2017
6/23/2017quarterly$0.643.52%7/12/20177/14/20178/15/2017
2/17/2017quarterly$0.644.14%4/11/20174/13/20175/15/2017
10/28/2016quarterly$0.644.44%1/11/20171/13/20172/15/2017
9/12/2016quarterly$0.573.56%10/12/201610/14/201611/15/2016
6/17/2016quarterly$0.573.8%7/13/20167/15/20168/15/2016
2/19/2016quarterly$0.574.2%4/13/20164/15/20165/16/2016
11/2/2015quarterly$0.573.6%1/13/20161/15/20162/16/2016
9/14/2015quarterly$0.513.46%10/13/201510/15/201511/14/2015
6/19/2015quarterly$0.512.94%7/13/20157/15/20158/14/2015
2/20/2015quarterly$0.513.33%4/13/20154/15/20155/15/2015
10/20/2014quarterly$0.493.48%1/13/20151/15/20152/13/2015
9/19/2014quarterly$0.422.86%10/10/201410/15/201411/17/2014
6/19/2014quarterly$0.423.15%7/11/20147/15/20148/15/2014
2/20/2014quarterly$0.423.29%4/11/20144/15/20145/15/2014
12/12/2013quarterly$0.403.06%1/13/20141/15/20142/14/2014
9/19/2013quarterly$0.403.34%10/10/201310/15/201311/15/2013
6/20/2013quarterly$0.403.75%7/11/20137/15/20138/15/2013
2/15/2013quarterly$0.404.19%4/11/20134/15/20135/15/2013
1/7/2013special$0.401/11/20131/15/20132/15/2013
1/4/2013quarterly$0.401/15/20132/15/2013
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading and Institutional Ownership History for AbbVie (NYSE ABBV)

Insider Ownership Percentage: 0.23%
Institutional Ownership Percentage: 67.65%
Insider Trades by Quarter for AbbVie (NYSE:ABBV)
Institutional Ownership by Quarter for AbbVie (NYSE:ABBV)

Insider Trades by Quarter for AbbVie (NYSE ABBV)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
11/10/2017Michael SeverinoEVPSell25,633$94.69$2,427,188.77View SEC Filing  
10/30/2017Henry O GosebruchInsiderSell18,300$90.55$1,657,065.00View SEC Filing  
9/28/2017Robert A MichaelVPSell6,699$88.00$589,512.00View SEC Filing  
9/11/2017Azita Saleki-GerhardtSVPSell8,300$85.02$705,666.00View SEC Filing  
8/7/2017Richard A GonzalezChairmanSell193,131$71.00$13,712,301.00View SEC Filing  
8/4/2017Richard A GonzalezChairmanSell87,899$71.02$6,242,586.98View SEC Filing  
8/3/2017Richard A GonzalezCEOSell65,861$71.00$4,676,131.00View SEC Filing  
7/31/2017Edward J RappDirectorBuy4,000$70.45$281,800.00View SEC Filing  
7/31/2017Henry O GosebruchInsiderSell18,000$70.09$1,261,620.00View SEC Filing  
6/14/2017Carlos AlbanEVPSell45,800$70.00$3,206,000.00View SEC Filing  
6/14/2017Laura J SchumacherInsiderSell79,800$70.00$5,586,000.00View SEC Filing  
5/19/2017Richard A GonzalezChairmanSell71,235$65.49$4,665,180.15View SEC Filing  
5/18/2017William J ChaseCFOSell38,300$65.35$2,502,905.00View SEC Filing  
5/4/2017Carlos AlbanEVPSell43,000$67.00$2,881,000.00View SEC Filing  
3/10/2017Laura J SchumacherInsiderSell40,000$65.26$2,610,400.00View SEC Filing  
3/10/2017Robert A MichaelVPSell5,132$65.29$335,068.28View SEC Filing  
3/10/2017Timothy J RichmondSVPSell22,451$65.29$1,465,825.79View SEC Filing  
3/8/2017Richard A GonzalezChairmanSell72,016$64.25$4,627,028.00View SEC Filing  
12/2/2016William J ChaseCFOSell6,600$59.19$390,654.00View SEC Filing  
9/7/2016Laura J SchumacherInsiderSell50,000$65.00$3,250,000.00View SEC Filing  
6/24/2016Laura J SchumacherEVPSell186,106$60.03$11,171,943.18View SEC Filing  
6/2/2016Richard A GonzalezCEOSell285,953$63.82$18,249,520.46View SEC Filing  
5/11/2016Richard A GonzalezCEOSell39,000$63.80$2,488,200.00View SEC Filing  
5/10/2016Carlos AlbanEVPSell47,438$63.52$3,013,261.76View SEC Filing  
5/10/2016Thomas A HurwichVPSell6,000$63.59$381,540.00View SEC Filing  
5/10/2016Timothy J RichmondSVPSell21,583$63.52$1,370,952.16View SEC Filing  
3/8/2016Laura J SchumacherEVPSell25,000$56.09$1,402,250.00View SEC Filing  
3/1/2016Timothy J RichmondSVPSell12,866$55.05$708,273.30View SEC Filing  
4/28/2015Richard A GonzalezCEOSell102,964$64.67$6,658,681.88View SEC Filing  
3/2/2015Laura J SchumacherEVPSell25,000$60.30$1,507,500.00View SEC Filing  
3/2/2015Timothy J RichmondSVPSell14,388$60.33$868,028.04View SEC Filing  
12/22/2014William J ChaseCFOSell8,495$68.00$577,660.00View SEC Filing  
3/4/2014Richard GonzalezCEOSell4,799$51.20$245,708.80View SEC Filing  
3/3/2014Azita Saleki-GerhardtSVPSell2,443$50.25$122,760.75View SEC Filing  
3/3/2014Carlos AlbanEVPSell2,882$50.09$144,359.38View SEC Filing  
3/3/2014William ChaseCFOSell3,948$50.22$198,268.56View SEC Filing  
9/17/2013Azita Saleki-GerhardtSVPSell10,473$45.84$480,082.32View SEC Filing  
8/19/2013Azita Saleki-GerhardtSVPSell1,270$43.01$54,622.70View SEC Filing  
8/12/2013Azita Saleki-GerhardtSVPSell8,851$44.91$397,498.41View SEC Filing  
3/11/2013Edward J RappDirectorBuy2,500$37.67$94,175.00View SEC Filing  
2/4/2013Frederick H WaddellDirectorBuy2,000$37.05$74,100.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for AbbVie (NYSE ABBV)

Source:
DateHeadline
AbbVie Inc. (ABBV) Receives Consensus Recommendation of "Buy" from AnalystsAbbVie Inc. (ABBV) Receives Consensus Recommendation of "Buy" from Analysts
www.americanbankingnews.com - November 23 at 7:56 PM
AbbVies (ABBV) "Hold" Rating Reiterated at BMO Capital MarketsAbbVie's (ABBV) "Hold" Rating Reiterated at BMO Capital Markets
www.americanbankingnews.com - November 22 at 1:44 PM
AbbVie (ABBV) Says Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at ASHAbbVie (ABBV) Says Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at ASH
www.streetinsider.com - November 21 at 8:55 PM
AbbVie Inc. (ABBV) PT Raised to $0.00AbbVie Inc. (ABBV) PT Raised to $0.00
www.americanbankingnews.com - November 21 at 8:14 PM
Phase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVies Commitment to Helping Blood Cancer PatientsPhase 3 MURANO Study of Venetoclax Chosen as Late-Breaking Abstract at the 2017 American Society of Hematology Annual Meeting & Exposition, Highlighting AbbVie's Commitment to Helping Blood Cancer Patients
finance.yahoo.com - November 21 at 3:55 PM
Better Buy: AbbVie Inc. vs. Johnson & JohnsonBetter Buy: AbbVie Inc. vs. Johnson & Johnson
www.fool.com - November 21 at 9:42 AM
Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017Enanta Pharmaceuticals Reports Financial Results for its Fourth Quarter and Year Ended September 30, 2017
www.businesswire.com - November 20 at 4:56 PM
ETFs with exposure to AbbVie, Inc. : November 20, 2017ETFs with exposure to AbbVie, Inc. : November 20, 2017
finance.yahoo.com - November 20 at 4:56 PM
High-Level Measures for Earnings Momentum Keep AbbVie (ABBV) a Strong BuyHigh-Level Measures for Earnings Momentum Keep AbbVie (ABBV) a Strong Buy
investorplace.com - November 20 at 11:19 AM
AbbVie Target of Unusually High Options Trading (ABBV)AbbVie Target of Unusually High Options Trading (ABBV)
www.americanbankingnews.com - November 18 at 3:56 AM
Roche's (RHHBY) Hemophilia A Drug Receives FDA ApprovalRoche's (RHHBY) Hemophilia A Drug Receives FDA Approval
finance.yahoo.com - November 17 at 11:04 AM
AbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive ConferenceAbbVie to Present at the Evercore ISI 2017 Biopharma Catalyst/Deep Dive Conference
finance.yahoo.com - November 16 at 10:34 AM
AbbVie Inc. (ABBV) Receives Hold Rating from BMO Capital MarketsAbbVie Inc. (ABBV) Receives Hold Rating from BMO Capital Markets
www.americanbankingnews.com - November 15 at 11:36 PM
3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock 3 Indisputable Reasons Why AbbVie Is the Best Big Pharma Stock
www.fool.com - November 15 at 9:22 PM
Tiaa Cref Investment Management Llc Buys DowDuPont Inc, Costco Wholesale Corp, AbbVie Inc, ... - NasdaqTiaa Cref Investment Management Llc Buys DowDuPont Inc, Costco Wholesale Corp, AbbVie Inc, ... - Nasdaq
www.nasdaq.com - November 14 at 3:25 PM
Novartis (NVS) Arm's Biosimilars Study Results EncourageNovartis (NVS) Arm's Biosimilars Study Results Encourage
finance.yahoo.com - November 14 at 3:25 PM
Understanding Sanofi’s Revenues by Segment in 3Q17Understanding Sanofi’s Revenues by Segment in 3Q17
finance.yahoo.com - November 14 at 3:25 PM
Amgen Gets Positive CHMP Opinion to Expand Nplate's LabelAmgen Gets Positive CHMP Opinion to Expand Nplate's Label
finance.yahoo.com - November 13 at 6:04 PM
AbbVie Inc. (ABBV) EVP Sells $2,427,188.77 in StockAbbVie Inc. (ABBV) EVP Sells $2,427,188.77 in Stock
www.americanbankingnews.com - November 13 at 5:43 PM
Earnings Momentum Analytics Power AbbVie (ABBV) to Strong BuyEarnings Momentum Analytics Power AbbVie (ABBV) to Strong Buy
investorplace.com - November 13 at 11:17 AM
AbbVie Inc. (ABBV) Stock Rating Upgraded by BidaskClubAbbVie Inc. (ABBV) Stock Rating Upgraded by BidaskClub
www.americanbankingnews.com - November 11 at 2:20 PM
7 Things AbbVie's Top Executives Just Said That You'll Want to Know7 Things AbbVie's Top Executives Just Said That You'll Want to Know
finance.yahoo.com - November 10 at 8:33 AM
You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018You'll Be Stunned by Gilead Sciences CEO's Prediction for 2018
finance.yahoo.com - November 9 at 4:19 PM
ETFs with exposure to AbbVie, Inc. : November 9, 2017ETFs with exposure to AbbVie, Inc. : November 9, 2017
finance.yahoo.com - November 9 at 4:19 PM
AbbVie, Inc. :ABBV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017AbbVie, Inc. :ABBV-US: Earnings Analysis: Q3, 2017 By the Numbers : November 8, 2017
finance.yahoo.com - November 8 at 5:16 PM
 Analysts Expect AbbVie Inc. (ABBV) Will Post Quarterly Sales of $7.56 Billion Analysts Expect AbbVie Inc. (ABBV) Will Post Quarterly Sales of $7.56 Billion
www.americanbankingnews.com - November 7 at 2:12 AM
Tax Reform: A Back Door To Killing Health Care, Medicare, And MoreTax Reform: A Back Door To Killing Health Care, Medicare, And More
finance.yahoo.com - November 6 at 4:03 PM
Bristol-Myers Squibb’s Major Developments in 3Q17Bristol-Myers Squibb’s Major Developments in 3Q17
finance.yahoo.com - November 6 at 4:03 PM
AbbVie (ABBV) a Buy on Robust Quant ScoreAbbVie (ABBV) a Buy on Robust Quant Score
investorplace.com - November 6 at 11:56 AM
Zacks: Analysts Expect AbbVie Inc. (ABBV) to Announce $1.43 EPSZacks: Analysts Expect AbbVie Inc. (ABBV) to Announce $1.43 EPS
www.americanbankingnews.com - November 5 at 9:08 PM
AbbVie Overpromises - BloombergAbbVie Overpromises - Bloomberg
www.bloomberg.com - November 5 at 3:24 PM
Investors Purchase Large Volume of Put Options on AbbVie (ABBV)Investors Purchase Large Volume of Put Options on AbbVie (ABBV)
www.americanbankingnews.com - November 4 at 1:28 AM
AbbVie continues to push for reversal of latest AndroGel verdictAbbVie continues to push for reversal of latest AndroGel verdict
www.reuters.com - November 4 at 1:16 AM
AbbVie OverpromisesAbbVie Overpromises
finance.yahoo.com - November 3 at 3:11 PM
Vertex Pops As Analyst Questions Whether Rival Has 'Viable Drug'Vertex Pops As Analyst Questions Whether Rival Has 'Viable Drug'
finance.yahoo.com - November 3 at 3:11 PM
AbbVie (ABBV) Announces Positive Phase 3 Extension Study Data for Elagolix for Management of Endometriosis with Associated PainAbbVie (ABBV) Announces Positive Phase 3 Extension Study Data for Elagolix for Management of Endometriosis with Associated Pain
www.streetinsider.com - November 3 at 11:41 AM
10-Q: NEUROCRINE BIOSCIENCES INC10-Q: NEUROCRINE BIOSCIENCES INC
www.marketwatch.com - November 3 at 11:41 AM
AbbVie to Present at the Jefferies 2017 London Healthcare ConferenceAbbVie to Present at the Jefferies 2017 London Healthcare Conference
finance.yahoo.com - November 3 at 11:41 AM
Physicians Financial Services, Inc. Buys DowDuPont Inc, Red Hat ... - NasdaqPhysicians Financial Services, Inc. Buys DowDuPont Inc, Red Hat ... - Nasdaq
www.nasdaq.com - November 2 at 8:22 PM
NBIX: INGREZZA® Revenues Way Ahead of Forecasts In 3Q17NBIX: INGREZZA® Revenues Way Ahead of Forecasts In 3Q17
finance.yahoo.com - November 2 at 8:22 PM
Bristol-Myers Squibb’s 3Q17 Earnings: OpdivoBristol-Myers Squibb’s 3Q17 Earnings: Opdivo
finance.yahoo.com - November 2 at 3:21 PM
Republican bill would get rid of tax credits for rare disease drugsRepublican bill would get rid of tax credits for rare disease drugs
finance.yahoo.com - November 2 at 3:21 PM
Top Stock Reports for AbbVie, Union Pacific & Bristol-MyersTop Stock Reports for AbbVie, Union Pacific & Bristol-Myers
finance.yahoo.com - November 1 at 8:14 PM
AbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated PainAbbVie Announces Positive Phase 3 Extension Study Data for Investigational Oral Treatment Elagolix for Management of Endometriosis with Associated Pain
finance.yahoo.com - November 1 at 3:11 PM
AbbVie Inc. (ABBV) Insider Sells $1,657,065.00 in StockAbbVie Inc. (ABBV) Insider Sells $1,657,065.00 in Stock
www.americanbankingnews.com - October 31 at 5:28 PM
How Did AbbVie Perform in 3Q17?How Did AbbVie Perform in 3Q17?
finance.yahoo.com - October 31 at 4:28 PM
AbbVie’s Humira and Imbruvica Saw Solid Growth in 3Q17AbbVie’s Humira and Imbruvica Saw Solid Growth in 3Q17
finance.yahoo.com - October 31 at 4:28 PM
HCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps ViewHCA Healthcare (HCA) Posts In-Line Q3 Earnings, Keeps View
finance.yahoo.com - October 31 at 4:28 PM
How AbbVie’s Drugs Performed in 3Q17How AbbVie’s Drugs Performed in 3Q17
finance.yahoo.com - October 31 at 4:28 PM
AbbVie (ABBV) a Buy on Strong Quant Score - Investorplace.comAbbVie (ABBV) a Buy on Strong Quant Score - Investorplace.com
investorplace.com - October 31 at 1:43 AM

Social Media

Financials

Chart

AbbVie (NYSE ABBV) Chart for Friday, November, 24, 2017
Loading chart…

This page was last updated on 11/24/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.